Stockreport

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 [Ya...

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF - ELIMINATE-B global Phase 1 study for chronic hepatitis B actively enrolling patients and will evaluate up to three dose administrations of PBGENE-HBV at each dose lev [Read more]